Jie Jiang, PhD, (Jie_Jiang@dfci.harvard.edu) focuses on the development of potent and selective kinase inhibitors for the treatment of NSCLC, including EGFR inhibitors, ALK inhibitors and ARAF inhibitors. The overall goal is to overcome the most common resistance mutations in EFGR/ALK/ARAF-mutant NSCLC.